The Diabetic Retinopathy Clinical Research Network has published the 2-year results of a 5-year study comparing intravitreous ranibizumab with panretinal laser photocoagulation in patients with proliferative diabetic retinopathy. The results suggest that intravitreous ranibizumab will become a valuable treatment option, although its exact role remains to be defined.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Time-dependent changes in hypoxia- and gliosis-related factors in experimental diabetic retinopathy
Eye Open Access 06 November 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am. J. Ophthalmol. 81, 383–396 (1976).
The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 88, 583–600 (1981).
Fine, S. L. & Patz, A. Ten years after the Diabetic Retinopathy Study. Ophthalmology 94, 739–740 (1987).
James, S., Gallagher, R., Dunbabin, J. & Perry, L. Prevalence of vascular complications and factors predictive of their development in young adults with type 1 diabetes: systematic literature review. BMC Res. Notes 7, 593 (2014).
Michaelides, M. et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117, 1078–1086 (2010).
National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. NICE technology appraisal guidance [TA346] [online], (2015).
National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema. NICE technology appraisal guidance [TA274] [online], (2013).
Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation versus intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314, 2137–2146 (2015).
Sivaprasad, S. et al. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. BMJ Open 5, e008405 (2015).
US National Library of Medicine. ClinicalTrials.gov[online], (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M.G. has received travel honoraria for conferences and consultancy fees for attending Advisory Boards from Allergan, Alimera, Bayer Healthcare and Novartis UK Ltd, and research funding from Novartis UK. S.M. has no competing interests to declare.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Gibson, J., McGinnigle, S. Intravitreous ranibizumab for proliferative diabetic retinopathy. Nat Rev Endocrinol 12, 130–131 (2016). https://doi.org/10.1038/nrendo.2016.1
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2016.1
